MTNB Matinas BioPharma Holdings Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: MTNB

Price (delayed)

$0.1823

Market cap

$39.65M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.11

Enterprise value

$38.42M

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has ...

Highlights
Matinas BioPharma Holdings's debt has decreased by 14% YoY and by 4.1% QoQ
The gross profit has dropped by 66% year-on-year and by 49% since the previous quarter
Matinas BioPharma Holdings's revenue has plunged by 66% YoY and by 49% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.matinasbiopharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of MTNB
Market
Shares outstanding
217.48M
Market cap
$39.65M
Enterprise value
$38.42M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.06
Price to sales (P/S)
36.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.05
Earnings
Revenue
$1.1M
EBIT
-$22.94M
EBITDA
-$22M
Free cash flow
-$15.5M
Per share
EPS
-$0.11
Free cash flow per share
-$0.07
Book value per share
$0.09
Revenue per share
$0.01
TBVPS
$0.11
Balance sheet
Total assets
$25.1M
Total liabilities
$5.86M
Debt
$3.56M
Equity
$19.25M
Working capital
$12.92M
Liquidity
Debt to equity
0.18
Current ratio
5.93
Quick ratio
5.27
Net debt/EBITDA
0.06
Margins
EBITDA margin
-2,007.4%
Gross margin
100%
Net margin
-2,093.2%
Operating margin
-2,168.4%
Efficiency
Return on assets
-72.2%
Return on equity
-89.2%
Return on invested capital
-91.8%
Return on capital employed
-102%
Return on sales
-2,093.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MTNB stock price

How has the Matinas BioPharma Holdings stock price performed over time
Intraday
1.28%
1 week
1.28%
1 month
-19.87%
1 year
-69.16%
YTD
-15.68%
QTD
-32.73%

Financial performance

How have Matinas BioPharma Holdings's revenue and profit performed over time
Revenue
$1.1M
Gross profit
$1.1M
Operating income
-$23.77M
Net income
-$22.94M
Gross margin
100%
Net margin
-2,093.2%
MTNB's operating margin has dropped by 181% year-on-year and by 100% since the previous quarter
Matinas BioPharma Holdings's net margin has shrunk by 113% QoQ
The gross profit has dropped by 66% year-on-year and by 49% since the previous quarter
Matinas BioPharma Holdings's revenue has plunged by 66% YoY and by 49% from the previous quarter

Growth

What is Matinas BioPharma Holdings's growth rate over time

Valuation

What is Matinas BioPharma Holdings stock price valuation
P/E
N/A
P/B
2.06
P/S
36.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.05
The EPS has contracted by 10% YoY
The company's equity fell by 47% YoY and by 17% QoQ
The stock's price to book (P/B) is 39% less than its 5-year quarterly average of 3.4 and 14% less than its last 4 quarters average of 2.4
Matinas BioPharma Holdings's revenue has plunged by 66% YoY and by 49% from the previous quarter
MTNB's P/S is 40% above its last 4 quarters average of 26.0

Efficiency

How efficient is Matinas BioPharma Holdings business performance
The ROS has plunged by 113% from the previous quarter
The ROE has dropped by 76% year-on-year and by 26% since the previous quarter
The return on assets has dropped by 72% year-on-year and by 25% since the previous quarter
Matinas BioPharma Holdings's ROIC has plunged by 60% YoY and by 26% from the previous quarter

Dividends

What is MTNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MTNB.

Financial health

How did Matinas BioPharma Holdings financials performed over time
Matinas BioPharma Holdings's total assets has decreased by 44% YoY and by 16% QoQ
MTNB's total liabilities is down by 28% year-on-year and by 12% since the previous quarter
Matinas BioPharma Holdings's debt is 82% lower than its equity
The company's debt to equity has surged by 64% YoY and by 13% QoQ
The company's equity fell by 47% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.